Attached files
| file | filename |
|---|---|
| EX-99.1 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | v171094_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
January
11, 2010
Date
of Report (Date of earliest event reported)
CHARLES RIVER
LABORATORIES INTERNATIONAL, INC.
(Exact
Name of Registrant as specified in its Charter)
______________
|
Delaware
|
333-92383
|
06-1397316
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
______________
|
251
Ballardvale Street
Wilmington,
Massachusetts 01887
|
|
(Address
of Principal Executive Offices) (Zip
Code)
|
781-222-6000
(Registrant’s
Telephone Number, including Area Code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 7.01
Regulation FD Disclosure
The
following information (including Exhibit 99.1) shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing.
On
January 11, 2009, Charles River Laboratories International, Inc. (the
“Registrant” or “Charles River”) issued a press release which announced that it
had decided to suspend operations at its Preclinical Services facility in
Shrewsbury, Massachusetts (PCS Massachusetts) by the middle of
2010. In addition, the Registrant will be presenting at the
J.P. Morgan 28th Annual
Healthcare Conference in San Francisco, California, on Wednesday, January
13th, at
10:00 a.m. PT (1:00 p.m. ET). Management of the Registrant intends to
present an overview of the Registrant’s strategic focus and business
developments. Included in this overview will be information related
to the suspension of operations at PCS Massachusetts. In advance of
the presentation, the Registrant has posted the accompanying slide presentation
on the Investor Relations section of the Registrant’s website at http://ir.criver.com. In
addition, a copy of the slide presentation is incorporated herein by reference
and filed as Exhibit 99.1 hereto.
The slide
presentation, attached as an exhibit to this report, includes "safe harbor"
language pursuant to the Private Securities Litigation Reform Act of 1995, as
amended, indicating that certain statements contained in the slide presentation
are "forward-looking" rather than historic. The slide presentation also states that
these and other risks relating to Charles River are set forth in the documents
filed by Charles River with the Securities and Exchange Commission.
ITEM
9.01. Financial Statements and
Exhibits
(a) Not
applicable.
(b) Not
applicable.
(c) Exhibits.
99.1 J.P
Morgan 28th Annual
Healthcare Conference Slide Presentation, dated January 13, 2010
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CHARLES
RIVER LABORATORIES
INTERNATIONAL,
INC.
|
||
|
Dated:
|
January
11, 2010
|
|
|
By:
|
/s/
Matthew L. Daniel
|
|
|
Matthew
L. Daniel, Senior Corporate Counsel
|
||
|
and
Assistant Secretary
|
||
|
Exhibit No.
|
Description
|
|
99.1
|
J.P
Morgan 28th
Annual Healthcare Conference Slide Presentation, dated January 13,
2010
|